An Efficacy, Safety Study to Evaluate Multiple Subcutaneous SHR-1918 in Combination With Lipid-Lowering Drugs for the Stable Treatment of Hyperlipidemic Patients With Poor Lipid Control-A Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Study
Latest Information Update: 29 Oct 2024
At a glance
- Drugs SHR-1918 (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Beijing Suncadia Pharmaceuticals
- 02 Sep 2024 Results(n=72) assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SHR-1918 in healthy subjects , presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
- 14 May 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2024 Status changed from not yet recruiting to recruiting.